$VKTX
Viking Therapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515220837 Filed on June 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.530M $320.0K $160.0K
YoY Change 200.0% 100.0%
% of Gross Profit
Research & Development $1.101M $139.0K $50.00K
YoY Change -94.82% 177.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.627M $461.0K $209.7K
YoY Change -87.93% 119.82%
Operating Profit -$2.627M -$461.0K -$209.7K
YoY Change -87.93% 119.82%
Interest Expense -$29.81K $35.25K $2.576K
YoY Change 213.24% 1268.52%
% of Operating Profit
Other Income/Expense, Net -$5.238M -$5.250M -$19.20K
YoY Change 409.97% 27240.01%
Pretax Income -$7.870M -$5.710M -$230.0K
YoY Change -65.45% 2382.61%
Income Tax
% Of Pretax Income
Net Earnings -$7.865M -$5.711M -$228.9K
YoY Change -65.48% 2394.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.074M -$1.403M -$26.59K
COMMON SHARES
Basic Shares Outstanding 9.783M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.70M $300.0K $100.0K
YoY Change 2311.11% 200.0%
Cash & Equivalents $9.497M $327.0K $78.85K
Short-Term Investments $12.20M
Other Short-Term Assets $600.0K $0.00 $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.27M $360.4K $100.0K
YoY Change 2374.41% 260.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $775.00 $200.0K
YoY Change -100.0% -99.61%
Total Long-Term Assets $0.00 $2.409M $200.0K
YoY Change -100.0% 1104.46%
TOTAL ASSETS
Total Short-Term Assets $22.27M $360.4K $100.0K
Total Long-Term Assets $0.00 $2.409M $200.0K
Total Assets $22.27M $2.769M $300.0K
YoY Change 1013.48% 823.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.008M $1.879M $400.0K
YoY Change -27.98% 369.85%
Accrued Expenses $200.0K $25.50M $0.00
YoY Change -99.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.700M $300.0K $0.00
YoY Change 466.67%
Total Short-Term Liabilities $4.876M $27.71M $400.0K
YoY Change -79.68% 6827.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.400M $200.0K
YoY Change -100.0% 600.0%
Other Long-Term Liabilities $0.00 $1.500M $100.0K
YoY Change -100.0% 1400.0%
Total Long-Term Liabilities $0.00 $2.900M $300.0K
YoY Change -100.0% 866.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.876M $27.71M $400.0K
Total Long-Term Liabilities $0.00 $2.900M $300.0K
Total Liabilities $4.876M $30.61M $800.0K
YoY Change -80.73% 3726.05%
SHAREHOLDERS EQUITY
Retained Earnings -$35.72M -$27.85M
YoY Change
Common Stock $29.25M $13.83K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.39M -$27.84M -$500.0K
YoY Change
Total Liabilities & Shareholders Equity $22.27M $2.769M $300.0K
YoY Change 1013.48% 823.11%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$7.865M -$5.711M -$228.9K
YoY Change -65.48% 2394.71%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.620M -$410.0K -$100.0K
YoY Change 268.18% 310.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$12.17M
YoY Change
Cash From Investing Activities -$12.17M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.97M -20.00K 0.000
YoY Change 1737.6%
NET CHANGE
Cash From Operating Activities -1.620M -410.0K -100.0K
Cash From Investing Activities -12.17M
Cash From Financing Activities 22.97M -20.00K 0.000
Net Change In Cash 9.180M -430.0K -100.0K
YoY Change 1033.33% 330.0%
FREE CASH FLOW
Cash From Operating Activities -$1.620M -$410.0K -$100.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000 shares
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9783312 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
174127
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78849
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6000000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6000000 shares
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2899669
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
13769
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
517892
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-27839043
CY2015Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1429993
CY2015Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
310350
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1879414
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27852872
CY2015Q1 us-gaap Liabilities
Liabilities
30608365
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2769322
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
60
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27708696
CY2015Q1 us-gaap Interest Payable Current
InterestPayableCurrent
112475
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
775
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
170367
CY2015Q1 us-gaap Assets
Assets
2769322
CY2015Q1 us-gaap Assets Current
AssetsCurrent
360398
CY2015Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2015Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2408149
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33391
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
327007
CY2015Q1 vktx Accrued License Fees Current
AccruedLicenseFeesCurrent
24826374
CY2015Q1 vktx Convertible Notes Payable Discount Noncurrent
ConvertibleNotesPayableDiscountNoncurrent
1070007
CY2015Q1 vktx Debt Conversion Feature Liability Current
DebtConversionFeatureLiabilityCurrent
62191
CY2015Q1 vktx Debt Conversion Feature Liability Noncurrent
DebtConversionFeatureLiabilityNoncurrent
1469676
CY2015Q1 vktx Convertible Notes Payable Discount Current
ConvertibleNotesPayableDiscountCurrent
0
CY2015Q1 vktx Amount Payable To Licensor To Exercise Option
AmountPayableToLicensorToExerciseOption
1000000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179619
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6000000 shares
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2654583
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
12866
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
380257
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-22128531
CY2014Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1264114
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
304274
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1830724
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22141457
CY2014Q4 us-gaap Liabilities
Liabilities
25171665
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3043134
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
60
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22517082
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77222
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
775
CY2014Q4 us-gaap Assets
Assets
3043134
CY2014Q4 us-gaap Assets Current
AssetsCurrent
773684
CY2014Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2268675
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17827
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
755857
CY2014Q4 vktx Accrued License Fees Current
AccruedLicenseFeesCurrent
19865863
CY2014Q4 vktx Convertible Notes Payable Discount Noncurrent
ConvertibleNotesPayableDiscountNoncurrent
1235886
CY2014Q4 vktx Debt Conversion Feature Liability Current
DebtConversionFeatureLiabilityCurrent
58742
CY2014Q4 vktx Debt Conversion Feature Liability Noncurrent
DebtConversionFeatureLiabilityNoncurrent
1390469
CY2014Q4 vktx Convertible Notes Payable Discount Current
ConvertibleNotesPayableDiscountCurrent
6076
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2 Tranche
CY2014Q1 vktx Payment For Option To Extend License Agreement
PaymentForOptionToExtendLicenseAgreement
50000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-100768
CY2014Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2675000 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
5433333 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2758333 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P11M5D
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-228941
CY2014Q1 us-gaap Revenues
Revenues
0
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7500
CY2014Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-209737
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19204
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
904
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-100770
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
209737
CY2014Q1 us-gaap Interest Expense
InterestExpense
2576
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2576
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
159737
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6379
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
115565
CY2014Q1 vktx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
189593
CY2014Q1 vktx Change In Fair Value Of Debt Conversion Feature
ChangeInFairValueOfDebtConversionFeature
10249
CY2014Q1 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
10249
CY2014Q1 vktx Non Cash Repurchase Of Common Stock
NonCashRepurchaseOfCommonStock
-1998
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Fair Value Option Methodology And Assumptions
FairValueOptionMethodologyAndAssumptions
There have been no changes in the methodologies used at March 31, 2015 or March 31, 2014.
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-410941
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2015Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1926391 shares
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6000000 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001607678
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-09-24
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Concentration of Credit Risk</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments that potentially subject the Company to a concentration of credit risk principally consist of cash. The Company maintains its cash balances at what it believes are high credit-quality financial institutions. At times, balances at a single financial institution may exceed federally insured limits of $250,000.</p> </div>
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Viking Therapeutics, Inc.
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p> </div>
CY2015Q1 dei Trading Symbol
TradingSymbol
VKTX
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4073609 shares
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M6D
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5711415
CY2015Q1 us-gaap Revenues
Revenues
0
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15564
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17909
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-461040
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5250375
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
903
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-428850
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
461040
CY2015Q1 us-gaap Interest Expense
InterestExpense
35253
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-17909
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138969
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
62707
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
322071
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
171955
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
37306
CY2015Q1 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
82656
CY2015Q1 vktx Anniversary Closing Date Of Initial Public Offering
AnniversaryClosingDateOfInitialPublicOffering
2016-05-04
CY2015Q1 vktx Net Proceeds From Issuance Of Capital Stock
NetProceedsFromIssuanceOfCapitalStock
5000000
CY2015Q1 vktx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
2057903
CY2015Q1 vktx Change In Fair Value Of Accrued License Fees
ChangeInFairValueOfAccruedLicenseFees
4960511
CY2015Q1 vktx Change In Fair Value Of Debt Conversion Feature
ChangeInFairValueOfDebtConversionFeature
82656

Files In Submission

Name View Source Status
0001193125-15-220837-index-headers.html Edgar Link pending
0001193125-15-220837-index.html Edgar Link pending
0001193125-15-220837.txt Edgar Link pending
0001193125-15-220837-xbrl.zip Edgar Link pending
d934973d10q.htm Edgar Link pending
d934973dex101.htm Edgar Link pending
d934973dex102.htm Edgar Link pending
d934973dex103.htm Edgar Link pending
d934973dex104.htm Edgar Link pending
d934973dex105.htm Edgar Link pending
d934973dex311.htm Edgar Link pending
d934973dex312.htm Edgar Link pending
d934973dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-20150331.xml Edgar Link completed
vktx-20150331.xsd Edgar Link pending
vktx-20150331_cal.xml Edgar Link unprocessable
vktx-20150331_def.xml Edgar Link unprocessable
vktx-20150331_lab.xml Edgar Link unprocessable
vktx-20150331_pre.xml Edgar Link unprocessable